vs
德康医疗（DXCM）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是德康医疗的1.7倍（$2.1B vs $1.3B），德康医疗净利率更高（21.2% vs 11.4%，领先9.8%），德康医疗同比增速更快（21.6% vs 9.3%），过去两年德康医疗的营收复合增速更高（12.0% vs 3.7%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
DXCM vs ZBH — 直观对比
营收规模更大
ZBH
是对方的1.7倍
$1.3B
营收增速更快
DXCM
高出12.3%
9.3%
净利率更高
DXCM
高出9.8%
11.4%
两年增速更快
DXCM
近两年复合增速
3.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $2.1B |
| 净利润 | $267.3M | $238.3M |
| 毛利率 | 62.9% | 64.6% |
| 营业利润率 | 25.6% | 17.9% |
| 净利率 | 21.2% | 11.4% |
| 营收同比 | 21.6% | 9.3% |
| 净利润同比 | 153.6% | 30.5% |
| 每股收益（稀释后） | $0.67 | $1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMZBH
| Q1 26 | $1.3B | $2.1B | ||
| Q4 25 | $1.3B | $2.2B | ||
| Q3 25 | $1.2B | $2.0B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $994.2M | $1.8B | ||
| Q2 24 | $1.0B | $1.9B |
净利润DXCMZBH
| Q1 26 | $267.3M | $238.3M | ||
| Q4 25 | $267.3M | $139.4M | ||
| Q3 25 | $283.8M | $230.9M | ||
| Q2 25 | $179.8M | $152.8M | ||
| Q1 25 | $105.4M | $182.0M | ||
| Q4 24 | $151.7M | $239.5M | ||
| Q3 24 | $134.6M | $249.1M | ||
| Q2 24 | $143.5M | $242.8M |
毛利率DXCMZBH
| Q1 26 | 62.9% | 64.6% | ||
| Q4 25 | 62.9% | 64.7% | ||
| Q3 25 | 60.5% | 72.1% | ||
| Q2 25 | 59.5% | 71.5% | ||
| Q1 25 | 56.9% | 71.2% | ||
| Q4 24 | 58.9% | 71.0% | ||
| Q3 24 | 59.7% | 70.5% | ||
| Q2 24 | 62.4% | 71.5% |
营业利润率DXCMZBH
| Q1 26 | 25.6% | 17.9% | ||
| Q4 25 | 25.6% | 6.9% | ||
| Q3 25 | 20.1% | 17.6% | ||
| Q2 25 | 18.4% | 14.4% | ||
| Q1 25 | 12.9% | 15.3% | ||
| Q4 24 | 17.0% | 19.2% | ||
| Q3 24 | 15.3% | 15.3% | ||
| Q2 24 | 15.7% | 18.1% |
净利率DXCMZBH
| Q1 26 | 21.2% | 11.4% | ||
| Q4 25 | 21.2% | 6.2% | ||
| Q3 25 | 23.5% | 11.5% | ||
| Q2 25 | 15.5% | 7.4% | ||
| Q1 25 | 10.2% | 9.5% | ||
| Q4 24 | 13.6% | 11.8% | ||
| Q3 24 | 13.5% | 13.7% | ||
| Q2 24 | 14.3% | 12.5% |
每股收益（稀释后）DXCMZBH
| Q1 26 | $0.67 | $1.22 | ||
| Q4 25 | $0.67 | $0.71 | ||
| Q3 25 | $0.70 | $1.16 | ||
| Q2 25 | $0.45 | $0.77 | ||
| Q1 25 | $0.27 | $0.91 | ||
| Q4 24 | $0.37 | $1.18 | ||
| Q3 24 | $0.34 | $1.23 | ||
| Q2 24 | $0.35 | $1.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $424.2M |
| 总债务越低越好 | — | $7.5B |
| 股东权益账面价值 | $2.7B | $12.7B |
| 总资产 | $6.3B | $22.7B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资DXCMZBH
| Q1 26 | $917.7M | $424.2M | ||
| Q4 25 | $917.7M | $591.9M | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.2B | $556.9M | ||
| Q1 25 | $904.9M | $1.4B | ||
| Q4 24 | $606.1M | $525.5M | ||
| Q3 24 | $621.2M | $569.0M | ||
| Q2 24 | $939.2M | $420.1M |
总债务DXCMZBH
| Q1 26 | — | $7.5B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DXCMZBH
| Q1 26 | $2.7B | $12.7B | ||
| Q4 25 | $2.7B | $12.7B | ||
| Q3 25 | $2.7B | $12.8B | ||
| Q2 25 | $2.6B | $12.5B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.1B | $12.5B | ||
| Q3 24 | $2.0B | $12.4B | ||
| Q2 24 | $2.4B | $12.7B |
总资产DXCMZBH
| Q1 26 | $6.3B | $22.7B | ||
| Q4 25 | $6.3B | $23.1B | ||
| Q3 25 | $7.5B | $23.5B | ||
| Q2 25 | $7.3B | $22.9B | ||
| Q1 25 | $6.8B | $22.2B | ||
| Q4 24 | $6.5B | $21.4B | ||
| Q3 24 | $6.4B | $21.7B | ||
| Q2 24 | $6.8B | $21.5B |
负债/权益比DXCMZBH
| Q1 26 | — | 0.59× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $359.4M |
| 自由现金流经营现金流 - 资本支出 | — | $245.9M |
| 自由现金流率自由现金流/营收 | — | 11.8% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.51× |
| 过去12个月自由现金流最近4个季度 | — | $1.4B |
8季度趋势，按日历期对齐
经营现金流DXCMZBH
| Q1 26 | — | $359.4M | ||
| Q4 25 | $294.0M | $517.4M | ||
| Q3 25 | $659.9M | $418.7M | ||
| Q2 25 | $303.0M | $378.2M | ||
| Q1 25 | $183.8M | $382.8M | ||
| Q4 24 | $301.4M | $506.3M | ||
| Q3 24 | $199.5M | $395.7M | ||
| Q2 24 | $279.4M | $369.4M |
自由现金流DXCMZBH
| Q1 26 | — | $245.9M | ||
| Q4 25 | $192.1M | $442.6M | ||
| Q3 25 | $579.4M | $363.7M | ||
| Q2 25 | $208.9M | $328.1M | ||
| Q1 25 | $96.8M | $338.2M | ||
| Q4 24 | $176.8M | $454.8M | ||
| Q3 24 | $88.3M | $351.2M | ||
| Q2 24 | $213.3M | $316.7M |
自由现金流率DXCMZBH
| Q1 26 | — | 11.8% | ||
| Q4 25 | 15.3% | 19.7% | ||
| Q3 25 | 47.9% | 18.2% | ||
| Q2 25 | 18.1% | 15.8% | ||
| Q1 25 | 9.3% | 17.7% | ||
| Q4 24 | 15.9% | 22.5% | ||
| Q3 24 | 8.9% | 19.3% | ||
| Q2 24 | 21.2% | 16.3% |
资本支出强度DXCMZBH
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 3.3% | ||
| Q3 25 | 6.7% | 2.7% | ||
| Q2 25 | 8.1% | 2.4% | ||
| Q1 25 | 8.4% | 2.3% | ||
| Q4 24 | 11.2% | 2.5% | ||
| Q3 24 | 11.2% | 2.4% | ||
| Q2 24 | 6.6% | 2.7% |
现金转化率DXCMZBH
| Q1 26 | — | 1.51× | ||
| Q4 25 | 1.10× | 3.71× | ||
| Q3 25 | 2.33× | 1.81× | ||
| Q2 25 | 1.69× | 2.48× | ||
| Q1 25 | 1.74× | 2.10× | ||
| Q4 24 | 1.99× | 2.11× | ||
| Q3 24 | 1.48× | 1.59× | ||
| Q2 24 | 1.95× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
